Antisense nucleic acid of methicillin-resistant staphylococcus aureus resistance gene mecA

A methicillin-resistant, drug-resistant gene technology, applied in the field of antisense nucleic acid against methicillin-resistant Staphylococcus aureus drug-resistant gene mecA, can solve the problem of no antisense nucleic acid, achieve broad application prospects, and inhibit MRSA The effect of drug resistance

Inactive Publication Date: 2009-04-29
FOURTH MILITARY MEDICAL UNIVERSITY
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is still no international unified standard for the design of antisense nucleic acid. Us

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antisense nucleic acid of methicillin-resistant staphylococcus aureus resistance gene mecA
  • Antisense nucleic acid of methicillin-resistant staphylococcus aureus resistance gene mecA
  • Antisense nucleic acid of methicillin-resistant staphylococcus aureus resistance gene mecA

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Example 1 Design of antisense thio-oligodeoxynucleotides (PS-ODNs) against mecA mRNA:

[0025]The genome sequence of the MRSA drug-resistant gene mecA (gene number GI: 2791983) was retrieved from GENBANK. The sequence is 2007 bp in length and encodes PBP2a, which determines the expression of MRSA drug resistance. According to the principle of base complementarity, the mRNA of mecA was obtained from the DNA sequence. We use RNAstructure 4.2 computer software for assisted design, screen out a series of antisense nucleic acid target sites, and design corresponding antisense nucleic acid based on these target sites. RNAstructure can predict the secondary structure of genes according to the principle of minimum free energy. Calculate the energy change when PS-ODN binds to each target, and according to the net energy (Overall ΔG) of PS-ODN binding to the target sequence, the energy required for PS-ODN binding to the linear target sequence (Duplex ΔG or Binding ΔG ), after PS...

Embodiment 2

[0028] Design and synthesis of embodiment 2 PCR primers:

[0029] According to the gene sequence of mecA and 16srRNA of MRSA reported in GeneBank, two pairs of specific amplification primers for mecA and 16srRNA were designed with the software PrimerPremier 5.0. The primers were verified to be highly specific by BLAST software, and were synthesized by Shanghai Bioengineering Technology Service Co., Ltd. The sequences are shown in Table 2.

[0030] Table 2 Design and synthesis of amplification primers

[0031]

Embodiment 3

[0032] The preparation of embodiment 3 anionic liposomes:

[0033] First, we prepared positively charged nanoparticles through electrostatic interaction between PEI and PS-ODN. Stearoylphosphatidylethanolamine (PEG 2000 -DSPE), the film dispersion method prepares anionic liposomes as the drug delivery system for transducing PS-ODN into the MRSA bacterial body.

[0034] In the following examples, the applicant selects PS-ODNs09, which has the best experimental results, as an example. Other thio-oligodeoxynucleotides are also tested according to the following methods.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to antisense oligodeoxynucleotide sequence aiming at a drug resistant gene mecA of a methicillin resistant staphylococcus aureus (MRSA), preparation for medicines containing the antisense oligodeoxynucleotide sequence, and application of the antisense oligodeoxynucleotide sequence. The antisense oligodeoxynucleotide sequence is characterized in that the antisense oligodeoxynucleotide sequence can be combined with different regions of the drug resistant gene mecA of the MRSA, and block the expression of the drug resistant gene mecA; the base sequence of the antisense oligodeoxynucleotide is PS-ODNs01-20; and the antisense oligodeoxynucleotide can be combined with a specific site of a target gene, so as to inhibit the expression of the drug resistant gene, restore the sensitivity of MRSA to beta-lactam antibiotics, and effectively resist the drug resistance of MRSA.

Description

technical field [0001] The invention relates to a kind of antisense nucleic acid sequence for methicillin-resistant Staphylococcus aureus (MRSA) drug-resistant gene mecA, preparation of medicine containing the antisense nucleic acid sequence and application thereof. Background technique [0002] At present, the problem of bacterial drug resistance has intensified around the world, and many bacterial infectious diseases that were once curable are becoming incurable diseases. MRSA is the most common and important pathogenic bacteria in clinical practice. Since MRSA was first discovered in 1961, especially after the 1980s, the infection rate of MRSA has shown an obvious upward trend in most areas. For example, the infection rate of MRSA in the United States has increased from 1974 to 2% in 2003 to nearly 60% in 2003, an increase of almost 30 times in 30 years; Italy rose from 6% in 1981 to 26% in 1996. With the continuous improvement of MRSA infection rate, its fatality rate i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N15/11A61K31/7088A61P31/04C12N15/113
Inventor 罗晓星孟静茹王慧贾敏侯征马雪何功浩
Owner FOURTH MILITARY MEDICAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap